DAM
PCRX icon

DLD Asset Management’s Pacira BioSciences PCRX Stock Holding History

DLD Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26,800
Closed -$1.22M – 116
2017
Q4 		$1.22M Buy
+26,800
New +$1.06M 0.09% 44

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

DLD Asset Management's PCRX Position: Q1 2018 in Review

DLD Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 86,500 shares — an estimated $3.08M sold.

DLD Asset Management first reported a position in PCRX in Q4 2017 and held it in 1 quarter. The position peaked at $3.95M in Q4 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • DLD Asset Management reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • DLD Asset Management sold 86,500 Pacira BioSciences shares in Q1 2018, an estimated $3.08M.
  • DLD Asset Management first reported a position in Pacira BioSciences in Q4 2017 and held it in 1 quarter.
  • DLD Asset Management's Pacira BioSciences position peaked at $3.95M in Q4 2017.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on DLD Asset Management's 13F filing for Q1 2018, filed 14 May 2018.